PL3463435T3 - Przeciwciała przeciwko alfa-synukleinie i ich zastosowania - Google Patents
Przeciwciała przeciwko alfa-synukleinie i ich zastosowaniaInfo
- Publication number
- PL3463435T3 PL3463435T3 PL17728525T PL17728525T PL3463435T3 PL 3463435 T3 PL3463435 T3 PL 3463435T3 PL 17728525 T PL17728525 T PL 17728525T PL 17728525 T PL17728525 T PL 17728525T PL 3463435 T3 PL3463435 T3 PL 3463435T3
- Authority
- PL
- Poland
- Prior art keywords
- synuclein
- antibodies
- alpha
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/46—Hybrid immunoglobulins
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/536—Immunoassay; Biospecific binding assay; Materials therefor with immune complex formed in liquid phase
- G01N33/537—Immunoassay; Biospecific binding assay; Materials therefor with immune complex formed in liquid phase with separation of immune complex from unbound antigen or antibody
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/577—Immunoassay; Biospecific binding assay; Materials therefor involving monoclonal antibodies binding reaction mechanisms characterised by the use of monoclonal antibodies
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
- G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/524—CH2 domain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/71—Decreased effector function due to an Fc-modification
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Organic Chemistry (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biochemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Microbiology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pathology (AREA)
- General Physics & Mathematics (AREA)
- Food Science & Technology (AREA)
- Analytical Chemistry (AREA)
- Biotechnology (AREA)
- Cell Biology (AREA)
- Physics & Mathematics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Psychology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662344746P | 2016-06-02 | 2016-06-02 | |
| EP17728525.1A EP3463435B1 (en) | 2016-06-02 | 2017-06-01 | Antibodies to alpha-synuclein and uses thereof |
| PCT/EP2017/063406 WO2017207739A1 (en) | 2016-06-02 | 2017-06-01 | Antibodies to alpha-synuclein and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL3463435T3 true PL3463435T3 (pl) | 2022-02-14 |
Family
ID=59021492
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL17728525T PL3463435T3 (pl) | 2016-06-02 | 2017-06-01 | Przeciwciała przeciwko alfa-synukleinie i ich zastosowania |
Country Status (37)
| Country | Link |
|---|---|
| US (5) | US10160800B2 (pl) |
| EP (2) | EP3463435B1 (pl) |
| JP (3) | JP7078552B2 (pl) |
| KR (1) | KR102499438B1 (pl) |
| CN (2) | CN109475616B (pl) |
| AR (1) | AR108663A1 (pl) |
| AU (2) | AU2017272804B2 (pl) |
| BR (1) | BR112018074978A2 (pl) |
| CA (1) | CA3025987A1 (pl) |
| CL (1) | CL2018003438A1 (pl) |
| CO (1) | CO2018014010A2 (pl) |
| CY (1) | CY1124896T1 (pl) |
| DK (1) | DK3463435T3 (pl) |
| EA (2) | EA038358B1 (pl) |
| EC (1) | ECSP18096095A (pl) |
| ES (1) | ES2903402T3 (pl) |
| GE (2) | GEAP202114964A (pl) |
| HR (1) | HRP20211935T1 (pl) |
| HU (1) | HUE057214T2 (pl) |
| IL (1) | IL263243A (pl) |
| LT (1) | LT3463435T (pl) |
| MA (1) | MA45125B1 (pl) |
| MD (1) | MD3463435T2 (pl) |
| MX (1) | MX393740B (pl) |
| MY (1) | MY188183A (pl) |
| PE (2) | PE20190440A1 (pl) |
| PH (1) | PH12018502538A1 (pl) |
| PL (1) | PL3463435T3 (pl) |
| PT (1) | PT3463435T (pl) |
| RS (1) | RS62682B1 (pl) |
| SG (1) | SG11201810420YA (pl) |
| SI (1) | SI3463435T1 (pl) |
| SM (1) | SMT202200008T1 (pl) |
| TW (2) | TW202309093A (pl) |
| UA (1) | UA124733C2 (pl) |
| WO (1) | WO2017207739A1 (pl) |
| ZA (1) | ZA201808582B (pl) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201512203D0 (en) | 2015-07-13 | 2015-08-19 | Lundbeck & Co As H | Agents,uses and methods |
| MA46836A (fr) | 2016-11-15 | 2019-09-25 | H Lundbeck As | Agents, utilisations et procédés pour le traitement d'une synucléinopathie |
| EP3555127B1 (en) | 2016-12-16 | 2024-12-18 | H. Lundbeck A/S | Agents, uses and methods |
| US10364286B2 (en) | 2016-12-22 | 2019-07-30 | H. Lundbeck A/S | Monoclonal anti-alpha-synuclein antibodies for preventing tau aggregation |
| EA201991720A1 (ru) | 2017-02-17 | 2020-01-20 | Бристол-Маерс Сквибб Компани | Антитела к альфа-синуклеину и их применения |
| GB201720970D0 (en) | 2017-12-15 | 2018-01-31 | Ucb Biopharma Sprl | Antibodies |
| GB201720975D0 (en) | 2017-12-15 | 2018-01-31 | Ucb Biopharma Sprl | Anti-alpha synuclein antibodies |
| WO2020079113A1 (en) * | 2018-10-19 | 2020-04-23 | Janssen Vaccines & Prevention B.V. | Anti-synuclein antibodies |
| TWI734279B (zh) | 2018-12-14 | 2021-07-21 | 美商美國禮來大藥廠 | 抗α-突觸核蛋白抗體及其用途 |
| KR20210154179A (ko) | 2019-04-18 | 2021-12-20 | 에이씨 이뮨 에스.에이. | 치료 및 진단용 신규한 분자 |
| CN110172098B (zh) * | 2019-05-27 | 2023-03-10 | 长春工业大学 | 抗α-突触核蛋白的单克隆抗体及其应用 |
| WO2021055881A1 (en) | 2019-09-20 | 2021-03-25 | Denali Therapeutics Inc. | Anti-alpha-synuclein antibodies and methods of use thereof |
| KR102239512B1 (ko) * | 2020-09-10 | 2021-04-12 | 서울대학교산학협력단 | 다중기능성 마이크로캡슐 조성물 및 그 제조방법 |
| US20250320283A1 (en) | 2020-10-16 | 2025-10-16 | Ac Immune Sa | Antibodies Binding to Alpha-Synuclein for Therapy and Diagnosis |
| CN112920274A (zh) * | 2021-03-17 | 2021-06-08 | 江苏贝格尔生物医药有限公司 | 一种检测alpha-synuclein蛋白的鼠单克隆抗体及其应用 |
| CN113912716B (zh) * | 2021-12-15 | 2022-03-01 | 北京凯祥弘康生物科技有限公司 | 针对α-突触核蛋白抗原的抗体及其应用 |
| WO2024141576A1 (en) | 2022-12-29 | 2024-07-04 | Astrazeneca Ab | Compositions and methods for treating alpha-synucleinopathies |
Family Cites Families (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1259615B1 (en) | 2000-03-03 | 2008-11-12 | Cambridge Antibody Technology Limited | Antibodies against eotaxin and their use |
| US7943129B2 (en) | 2000-05-26 | 2011-05-17 | National Research Council Of Canada | Single-domain brain-targeting antibody fragments derived from llama antibodies |
| EP2082749A3 (en) | 2000-07-07 | 2010-06-30 | Bioarctic Neuroscience AB | Prevention and treatment of Alzheimer's disease |
| US8506959B2 (en) | 2002-11-01 | 2013-08-13 | Neotope Biosciences Limited | Prevention and treatment of synucleinopathic and amyloidogenic disease |
| US9034337B2 (en) | 2003-10-31 | 2015-05-19 | Prothena Biosciences Limited | Treatment and delay of outset of synucleinopathic and amyloidogenic disease |
| TW200509968A (en) | 2002-11-01 | 2005-03-16 | Elan Pharm Inc | Prevention and treatment of synucleinopathic disease |
| US20080014194A1 (en) | 2003-10-31 | 2008-01-17 | Elan Pharmaceuticals, Inc. | Prevention and Treatment of Synucleinopathic and Amyloidogenic Disease |
| US7358331B2 (en) | 2003-05-19 | 2008-04-15 | Elan Pharmaceuticals, Inc. | Truncated fragments of alpha-synuclein in Lewy body disease |
| PL1633189T3 (pl) | 2003-05-19 | 2017-12-29 | Prothena Biosciences Limited | Skrócone fragmenty alfa-synukleiny w chorobie z ciałami lewy'ego |
| WO2005047860A2 (en) | 2003-11-08 | 2005-05-26 | Elan Pharmaceuticals, Inc. | Antibodies to alpha-synuclein |
| MX2007001679A (es) | 2004-08-09 | 2007-05-23 | Elan Pharm Inc | Prevencion y tratamiento de la enfermedad sinucleinopatica y amiloidogenica. |
| CA2623841C (en) | 2005-09-27 | 2019-03-12 | National Research Council Of Canada | Methods of identifying agents capable of tmem30a mediated transmigration across the blood brain barrier (bbb) |
| PL2118300T3 (pl) | 2007-02-23 | 2015-11-30 | Prothena Biosciences Ltd | Zapobieganie i leczenie synukleinopatii i amyloidozy |
| US8147833B2 (en) | 2007-02-23 | 2012-04-03 | Neotope Biosciences Limited | Prevention and treatment of synucleinopathic and amyloidogenic disease |
| JP4934074B2 (ja) | 2007-03-07 | 2012-05-16 | 株式会社アルファ | スイッチ固定構造 |
| DK2282758T3 (en) | 2008-04-29 | 2019-02-25 | Bioarctic Ab | ANTIBODIES AND VACCINES FOR USE IN THERAPEUTIC AND DIAGNOSTIC PROCEDURES FOR ALPHA-SYNUCLEIN-RELATED DISORDERS |
| WO2010069603A1 (en) | 2008-12-19 | 2010-06-24 | Neurimmune Therapeutics Ag | Human anti-alpha-synuclein autoantibodies |
| JP4654348B1 (ja) | 2010-02-23 | 2011-03-16 | 多摩川精機株式会社 | 検出装置用巻線の正弦波巻線方法 |
| EP2539366B1 (en) * | 2010-02-26 | 2017-11-08 | BioArtic Neuroscience AB | Protofibril-binding antibodies and their use in therapeutic and diagnostic methods for parkinson's disease, dementia with lewy bodies and other alpha-synucleinopathies |
| CN103796679B (zh) | 2011-06-23 | 2016-10-19 | 比奥根国际神经科学公司 | 抗-α突触核蛋白结合分子 |
| HRP20230065T1 (hr) | 2011-10-28 | 2023-03-03 | Prothena Biosciences Limited | Humanizirana protutijela koja prepoznaju alfa-sinuklein |
| UA118441C2 (uk) | 2012-10-08 | 2019-01-25 | Протена Біосаєнсиз Лімітед | Антитіло, що розпізнає альфа-синуклеїн |
| US9534044B2 (en) * | 2013-02-28 | 2017-01-03 | United Arab Emirates University | Alpha-synuclein antibodies and uses thereof |
| CA2924268C (en) * | 2013-11-21 | 2021-05-18 | F. Hoffmann-La Roche Ag | Anti-alpha-synuclein antibodies and methods of use |
| KR102781223B1 (ko) | 2014-11-10 | 2025-03-12 | 메디뮨 리미티드 | Cd73에 특이적인 결합 분자 및 이의 용도 |
-
2017
- 2017-06-01 CN CN201780045951.2A patent/CN109475616B/zh active Active
- 2017-06-01 HU HUE17728525A patent/HUE057214T2/hu unknown
- 2017-06-01 EP EP17728525.1A patent/EP3463435B1/en active Active
- 2017-06-01 RS RS20211502A patent/RS62682B1/sr unknown
- 2017-06-01 TW TW111117603A patent/TW202309093A/zh unknown
- 2017-06-01 PE PE2018003155A patent/PE20190440A1/es unknown
- 2017-06-01 GE GEAP202114964A patent/GEAP202114964A/en unknown
- 2017-06-01 CN CN202211223767.1A patent/CN116120445A/zh active Pending
- 2017-06-01 UA UAA201811679A patent/UA124733C2/uk unknown
- 2017-06-01 MA MA45125A patent/MA45125B1/fr unknown
- 2017-06-01 SI SI201731025T patent/SI3463435T1/sl unknown
- 2017-06-01 EA EA201892548A patent/EA038358B1/ru unknown
- 2017-06-01 HR HRP20211935TT patent/HRP20211935T1/hr unknown
- 2017-06-01 SM SM20220008T patent/SMT202200008T1/it unknown
- 2017-06-01 MX MX2018014456A patent/MX393740B/es unknown
- 2017-06-01 JP JP2018563050A patent/JP7078552B2/ja active Active
- 2017-06-01 MY MYPI2018002168A patent/MY188183A/en unknown
- 2017-06-01 WO PCT/EP2017/063406 patent/WO2017207739A1/en not_active Ceased
- 2017-06-01 PE PE2023002924A patent/PE20250392A1/es unknown
- 2017-06-01 PT PT177285251T patent/PT3463435T/pt unknown
- 2017-06-01 ES ES17728525T patent/ES2903402T3/es active Active
- 2017-06-01 TW TW106118078A patent/TWI765890B/zh active
- 2017-06-01 MD MDE20190406T patent/MD3463435T2/ro unknown
- 2017-06-01 AU AU2017272804A patent/AU2017272804B2/en active Active
- 2017-06-01 AR ARP170101504A patent/AR108663A1/es unknown
- 2017-06-01 EA EA202191380A patent/EA202191380A1/ru unknown
- 2017-06-01 BR BR112018074978-8A patent/BR112018074978A2/pt active Search and Examination
- 2017-06-01 SG SG11201810420YA patent/SG11201810420YA/en unknown
- 2017-06-01 LT LTEPPCT/EP2017/063406T patent/LT3463435T/lt unknown
- 2017-06-01 CA CA3025987A patent/CA3025987A1/en active Pending
- 2017-06-01 KR KR1020187037675A patent/KR102499438B1/ko active Active
- 2017-06-01 EP EP21202106.7A patent/EP4000632A1/en active Pending
- 2017-06-01 DK DK17728525.1T patent/DK3463435T3/da active
- 2017-06-01 PL PL17728525T patent/PL3463435T3/pl unknown
- 2017-06-01 US US15/611,416 patent/US10160800B2/en active Active
- 2017-06-01 GE GEAP201714964A patent/GEP20217253B/en unknown
-
2018
- 2018-10-25 US US16/170,468 patent/US10889639B2/en active Active
- 2018-11-22 IL IL263243A patent/IL263243A/en unknown
- 2018-11-29 PH PH12018502538A patent/PH12018502538A1/en unknown
- 2018-11-30 CL CL2018003438A patent/CL2018003438A1/es unknown
- 2018-12-19 ZA ZA2018/08582A patent/ZA201808582B/en unknown
- 2018-12-21 CO CONC2018/0014010A patent/CO2018014010A2/es unknown
- 2018-12-28 EC ECSENADI201896095A patent/ECSP18096095A/es unknown
-
2020
- 2020-12-03 US US17/111,159 patent/US11560424B2/en active Active
-
2022
- 2022-01-05 CY CY20221100010T patent/CY1124896T1/el unknown
- 2022-05-19 JP JP2022082099A patent/JP2022110117A/ja active Pending
-
2023
- 2023-01-20 US US18/099,671 patent/US20230331830A1/en active Pending
-
2024
- 2024-01-31 AU AU2024200601A patent/AU2024200601A1/en active Pending
- 2024-06-27 JP JP2024103562A patent/JP7823118B2/ja active Active
-
2025
- 2025-01-16 US US19/025,554 patent/US20250263477A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL268243A (en) | Antibodies to alpha-synuclein and their uses | |
| IL283321A (en) | Antibodies against muc16 and their uses | |
| ZA201808582B (en) | Antibodies to alpha-synuclein and uses thereof | |
| IL258284A (en) | Anti-Lag 3 antibodies and their uses | |
| IL259585A (en) | Antibody molecules for april and their uses | |
| ZA201800536B (en) | Il-8-binding antibodies and uses thereof | |
| IL257263A (en) | Antibodies against angptl8 and their use | |
| SG11201808632YA (en) | Anti-pacap antibodies and uses thereof | |
| IL254954A0 (en) | Anti-pacap antibodies and their uses | |
| ZA201901935B (en) | Anti-il-33 antibodies and uses thereof | |
| HUE069499T2 (hu) | Terápiás ellenanyagok és alkalmazásaik | |
| ZA201704943B (en) | Antibodies to tau and uses thereof | |
| PL3292154T3 (pl) | Przeciwciała przeciwko ludzkiemu HER3 i ich zastosowania | |
| GB201503387D0 (en) | Anti-carbapenem antibodies and uses thereof | |
| IL266082A (en) | Anti-chikv antibodies and their use | |
| IL266049A (en) | Antibodies against o1 and their uses | |
| IL264417A (en) | Anti-o2 antibodies and their uses | |
| SG11201705748SA (en) | Anti-glycoprotein antibodies and uses thereof | |
| HK40007492A (en) | Antibodies to alpha-synuclein and uses thereof |